The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: Analysis of the intraventricular fluid from parkinsonian patients

被引:51
作者
Maruyama, W
Naoi, M
Narabayashi, H
机构
[1] NAGOYA INST TECHNOL,DEPT BIOSCI,SHOWA KU,NAGOYA,AICHI 466,JAPAN
[2] NAGOYA UNIV,SCH MED,DEPT NEUROL,SHOWA KU,NAGOYA,AICHI 466,JAPAN
[3] NEUROL CLIN,MEGURO KU,TOKYO 153,JAPAN
关键词
Parkinsons disease; L-DOPA; L-threo-dihydroxyphenylserine; intraventricular fluid; monoamine; catechol-o-methyltransferase;
D O I
10.1016/0022-510X(96)00049-4
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The monoamines and their metabolites were analyzed in the intraventricular fluid of parkinsonian patients treated with L-DOPA alone or together with L-threo-3,4-dihydroxyphenyl serine (L-threo-DOPS), the precursor amino acids of dopamine and noradrenaline, respectively. In the intraventricular fluid of the patients administered with L-DOPA, the level of dopamine metabolites were higher than control, suggesting enhanced turnover of dopamine in the brain. However, L-DOPA administration increased free noradrenaline only slightly, and did not affect serotonin and its metabolite. On the other hand, by administration of L-DOPA combined with L-threo-DOPS, the levels of monoamines increased in general, whereas the monoamine metabolites by catechol-O-methyltransferase were reduced compared with those in the patients treated with L-DOPA alone. Only a minor part of L-threo-DOPS was metabolized into noradrenaline by aromatic L-amino acid decarboxylase, and it was metabolized mainly by two other enzymes, catechol-O-methyltransferase and DOPS-aldolase in the brain. An overview of the metabolism of neurotransmitters in the brain proved to be useful to evaluate the therapeutic effects of these precursor amino acids.
引用
收藏
页码:141 / 148
页数:8
相关论文
共 15 条
  • [1] ABHAIRD NN, 1990, ADV NEUROL, V53, P489
  • [2] DOES LONG-TERM AGGRAVATION OF PARKINSONS-DISEASE RESULT FROM NONDOPAMINERGIC LESIONS
    BONNET, AM
    LORIA, Y
    SAINTHILAIRE, MH
    LHERMITTE, F
    AGID, Y
    [J]. NEUROLOGY, 1987, 37 (09) : 1539 - 1542
  • [3] MONOAMINE METABOLITES IN LUMBAR CSF - QUESTION OF THEIR ORIGIN IN RELATION TO CLINICAL STUDIES
    GARELIS, E
    YOUNG, SN
    LAL, S
    SOURKES, TL
    [J]. BRAIN RESEARCH, 1974, 79 (01) : 1 - 8
  • [4] SUBSTRATE STEREOSPECIFICITY AND SELECTIVITY OF CATECHOL-O-METHYLTRANSFERASE FOR DOPA, DOPA DERIVATIVES AND ALPHA-SUBSTITUTED CATECHOLAMINES
    GORDONSMITH, RH
    RAXWORTHY, MJ
    GULLIVER, PA
    [J]. BIOCHEMICAL PHARMACOLOGY, 1982, 31 (03) : 433 - 437
  • [5] RELATION BETWEEN PLASMA AND CEREBROSPINAL-FLUID LEVELS OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL
    KOPIN, IJ
    GORDON, EK
    JIMERSON, DC
    POLINSKY, RJ
    [J]. SCIENCE, 1983, 219 (4580) : 73 - 75
  • [6] A NEW METABOLIC PATHWAY OF L-THREO-3,4-DIHYDROXYPHENYLSERINE, A PRECURSOR AMINO-ACID OF NOREPINEPHRINE, IN THE BRAIN STUDIES BY IN-VIVO MICRODIALYSIS
    MARUYAMA, W
    NAKAHARA, D
    NAOI, M
    [J]. JOURNAL OF NEURAL TRANSMISSION-PARKINSONS DISEASE AND DEMENTIA SECTION, 1994, 7 (01) : 21 - 33
  • [7] Maruyama W, 1994, Rinsho Shinkeigaku, V34, P991
  • [8] THE MECHANISM OF PERTURBATION IN MONOAMINE METABOLISM BY L-DOPA THERAPY - INVIVO AND INVITRO STUDIES
    MARUYAMA, W
    NAOI, M
    TAKAHASHI, A
    WATANABE, H
    KONAGAYA, Y
    MOKUNO, K
    HASEGAWA, S
    NAKAHARA, D
    [J]. JOURNAL OF NEURAL TRANSMISSION-GENERAL SECTION, 1992, 90 (03) : 183 - 197
  • [9] DOPAMINE BETA-HYDROXYLASE ACTIVITY IN CEREBROSPINAL-FLUID OF PARKINSONIAN-PATIENTS
    NAGATSU, T
    WAKUI, Y
    KATO, T
    FUJITA, K
    KONDO, T
    YOKOCHI, F
    NARABAYASHI, H
    [J]. BIOMEDICAL RESEARCH-TOKYO, 1982, 3 (01): : 95 - 98
  • [10] NAOI M, 1987, BIOCHEM BIOPH RES CO, V13, P482